US development of GCS 100 discontinued in Chronic Kidney Disease-La Jolla Pharma
La Jolla Pharma has decided to discontinue development of its polysaccharide-based galectin-3 inhibitor GCS-100 for Chronic Kidney Disease. This is due to the challenge of regulatory requirements - in particular the FDA has indicated that the Company would be required to conduct additional chemical characterization of GCS-100 prior to further clinical development. The Company believes that the timeframe and ultimate success of developing analytical methods that would satisfy the FDA's requirements are highly uncertain.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins